Skip to main content
. 2010 May 15;1(1):22–33. doi: 10.18632/oncotarget.105

Fig. 1. Increased CKS1B expression in relapsed myeloma links a short postrelapse survival.

Fig. 1

(A) CKS1B signal for 51 paired arrays was obtained at diagnosis and relapse. The high risk (quartile 4) reference line is taken from the complete (n=351) sample of arrays at diagnosis. Note that a majority of samples showed increased expression at relapse; the most dramatic changes were observed in patients with expression levels in quartiles 1–3 at diagnosis. A paired Student t test was used to compare log-scale signal at diagnosis and relapse. (B) Kaplan-Meier analysis of postrelapse survival is shown in relation to CKS1B expression from low expression at baseline (BL-Low) to low expression at relapse (RL-Low; n = 15) and BL-Low to high expression at relapse (RL-High; n = 23) and already high expression at baseline (BL-High; n = 13) determined by microarray. At the time of analysis, the median follow-up of a post-relapse survival was 14 months (range, 0.3 to 50 months) in this analysis..